TNF blockers are a class of biologic drugs that intercept a powerful inflammatory protein called tumor necrosis factor-alpha (TNF-α) before it can trigger or sustain the chronic inflammation behind conditions like rheumatoid arthritis, psoriasis, and inflammatory bowel disease. Since the first TNF blocker reached the market in 1998, these drugs have become some of the most prescribed biologics in medicine, generating a market worth tens of billions of dollars annually. Their mechanism sounds straightforward, but the reality is more layered than simple “blocking,” and the consequences of dampening such a central immune signal ripple into territory that matters for anyone considering or already on this therapy.
What TNF-α Does in a Healthy Body
TNF-α was originally named for its ability to cause tumor cells to die, but researchers have since learned that it plays a much broader role in immune regulation. In normal amounts, TNF-α helps coordinate the body’s defense against infections and injuries. It signals immune cells to gather at a site of damage, promotes the formation of structures called granulomas that wall off certain pathogens like tuberculosis bacteria, and influences whether cells survive, divide, or self-destruct. It works by binding to two receptors on cell surfaces, known as TNFR1 and TNFR2, each of which kicks off somewhat different downstream effects.1PubMed Central. The Role of Tumor Necrosis Factor Alpha (TNF-α) in Autoimmune Disease and Current TNF-α Inhibitors in Therapeutics TNFR1 tends to drive inflammation and can trigger cell death, while TNFR2 is more involved in immune cell survival and the regulation of certain protective T cells.2PubMed Central. TNFR1 and TNFR2 in the Control of the Life and Death Balance of Macrophages
Trouble starts when TNF-α signaling becomes excessive or misdirected. In autoimmune diseases, the immune system misfires, producing far too much TNF-α in tissues where there is no real threat. In the joints of someone with rheumatoid arthritis, for instance, TNF-α drives a cascade that promotes synovial inflammation and accelerates the destruction of cartilage and bone.3PubMed. TNF-α Promotes Synovial Inflammation and Cartilage Bone Destruction in Rheumatoid Arthritis via NF-κB/YY1/miR-103a-3p Axis In psoriasis, runaway TNF-α keeps the skin locked in a cycle of abnormal thickening and inflammation. In Crohn’s disease and ulcerative colitis, it fuels the intestinal tissue damage that causes pain, bleeding, and scarring. TNF blockers aim to break these cycles by neutralizing the excess protein.
Two Structural Families of TNF Blockers
Not all TNF blockers are built the same way. There are two main structural categories, and the differences in their design lead to real differences in how they interact with TNF-α molecules.
The first category is monoclonal antibodies, which are lab-engineered proteins shaped like the Y-shaped antibodies your immune system naturally makes. Infliximab and adalimumab are the best-known examples. These antibodies latch onto TNF-α and can form large, multi-molecule clusters with it. Infliximab, for instance, forms complexes with TNF-α that can reach extremely high molecular weights, while adalimumab forms somewhat smaller but still substantial clusters.4PubMed. Binding characteristics of tumor necrosis factor receptor-Fc fusion proteins vs anti-tumor necrosis factor mAbs This large-cluster formation is thought to be one reason these antibodies are effective in certain diseases where etanercept, the other class, is not.
The second category is the receptor-fusion protein, represented by etanercept. Rather than being an antibody, etanercept is essentially a decoy. It mimics the natural TNF receptor, tricking TNF-α molecules into binding to it instead of the real receptors on cells. Etanercept forms much smaller complexes with TNF-α and does not create the large aggregates that monoclonal antibodies do. This structural distinction helps explain why etanercept works well in rheumatoid arthritis and psoriasis but has not been effective in inflammatory bowel disease, where the antibody-type blockers have.5PubMed Central. Molecular mechanism of action of anti-tumor necrosis factor antibodies in inflammatory bowel diseases
A third variant worth knowing about is certolizumab pegol, a monoclonal antibody fragment attached to a polymer called polyethylene glycol. Unlike the other antibodies, it lacks the Fc portion of the antibody structure. This matters for pregnancy, as we will see, and also means it does not trigger certain immune responses in the same way.
More Than Simple Neutralization
Early thinking held that TNF blockers simply mop up the excess TNF-α floating around in inflamed tissue. That turns out to be an oversimplification. Research over the past two decades has revealed that these drugs affect the immune system in several additional ways beyond just neutralizing free TNF-α.
TNF-α exists in two forms in the body: a membrane-bound form (tmTNF-α) that sits on the surface of the cells producing it, and a soluble form (sTNF-α) that is snipped free and floats to distant targets. All currently available TNF blockers bind to both forms. When they bind the membrane-bound form, they can trigger what is called reverse signaling, sending a signal back into the cell that made the TNF-α. This reverse signaling can suppress the activity of those cells and even cause their death.6Nature Communications. The structural basis for the selective antagonism of soluble TNF-alpha by shark variable new antigen receptors In psoriasis, for example, infliximab does more than just reduce inflammation: it triggers a form of programmed cell death in the abnormal skin cells that make up psoriatic plaques.7British Journal of Dermatology. Programmed cell death of keratinocytes in infliximab‐treated plaque‐type psoriasis Adalimumab, meanwhile, rapidly restores normal skin cell behavior, promoting the return of healthy differentiation markers within days of starting treatment.8PubMed Central. Targeting TNFalpha rapidly reduces density of dendritic cells and macrophages in psoriatic plaques with restoration of epidermal keratinocyte differentiation
This complexity is part of why TNF blockers can be so effective. They do not just turn down one dial; they recalibrate multiple arms of the immune response in inflamed tissues.
The Infection Trade-Off
Because TNF-α is genuinely important for fighting infections, dampening it carries an inherent trade-off. Doctors prescribing TNF blockers need to weigh the benefit of controlling a destructive autoimmune process against the cost of reducing the patient’s ability to contain certain infections.9PubMed Central. Clinical use of anti-TNF therapy and increased risk of infections
The infection that gets the most attention is tuberculosis. TNF-α is critical for maintaining the granulomas that keep latent TB bacteria walled off and dormant. When you take a TNF blocker, those granulomas can lose their structural integrity, releasing the bacteria and allowing the infection to reactivate. The risk of developing TB goes up roughly 2 to 25 times depending on which TNF blocker is used and the background rate of TB in the population, with most reactivations happening soon after starting therapy and progressing rapidly.10European Respiratory Journal. The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement This is why screening for latent TB before starting any TNF blocker is standard practice worldwide. If latent TB is found, treatment for it typically begins before the biologic does.11PubMed Central. Reactivation of latent tuberculosis with TNF inhibitors: critical role of the beta 2 chain of the IL-12 receptor
Beyond TB, other opportunistic infections can also emerge, including certain fungal infections and viral reactivations. Lifetime risk estimates put the TB risk during TNF blocker use anywhere from negligible in low-prevalence settings to over 17% in high-prevalence ones, compared to a general population baseline of about 0.3%.12PubMed. Comparing the lifetime risks of TNF-alpha inhibitor use to common benchmarks of risk The practical takeaway: staying current on vaccinations, avoiding known exposures, and reporting fevers or unusual symptoms early are all more important once you are on these drugs.
When the Body Fights the Drug
One of the more frustrating aspects of TNF blocker therapy is that the body can develop antibodies against the drug itself, a problem called immunogenicity. Because TNF blockers are proteins, the immune system sometimes recognizes them as foreign and mounts an antibody response against them. These anti-drug antibodies can neutralize the medication, lowering its effective concentration in the blood and leading to a loss of response over time.
This is a significant clinical problem. The risk varies by drug, with infliximab and adalimumab being more immunogenic than etanercept. One of the best-established strategies for reducing this risk is taking methotrexate alongside the TNF blocker. Methotrexate suppresses the immune response that produces these anti-drug antibodies.13PubMed Central. Pharmacological strategies for mitigating anti-TNF biologic immunogenicity in rheumatoid arthritis patients Research on adalimumab patients has shown that when methotrexate was tapered and stopped, the rate of detectable anti-drug antibodies jumped from about 18% to 68%, though this did not always immediately affect how quickly the drug was cleared from the body.14Arthritis & Rheumatology. Anti-drug Antibodies Formation During Tapering and Stopping of Methotrexate in Rheumatoid Arthritis Patients with Longstanding Use of Adalimumab
This is one reason doctors sometimes check drug levels and anti-drug antibody levels in patients whose disease starts flaring after a period of good control. This approach, called therapeutic drug monitoring, helps distinguish between a patient who needs a higher dose and one whose drug is being neutralized by antibodies and who would benefit from switching to a different TNF blocker or a different drug class entirely. A meta-analysis of 26 studies found that proactive drug monitoring, done on a schedule rather than waiting for a flare, reduced the risk of treatment failure by about a third compared to standard care.15Wiley Online Library. Meta-analysis: The efficacy of therapeutic drug monitoring of anti-TNF-therapy in inflammatory bowel disease
Paradoxical Psoriasis
Among the more counterintuitive side effects of TNF blockers is the development of psoriasis in patients who are taking the drug for a completely different condition, or the worsening of psoriasis in patients already being treated for it. This phenomenon, called paradoxical psoriasis, affects roughly 2 to 5% of patients on anti-TNF therapy.16Nature Communications. TNF blockade induces a dysregulated type I interferon response without autoimmunity in paradoxical psoriasis
The mechanism behind this is genuinely different from ordinary psoriasis. Research has shown that paradoxical psoriasis is driven by an overproduction of type I interferons from a specific type of immune cell called plasmacytoid dendritic cells. Normally, TNF-α helps these cells mature and stop producing interferons. When TNF blockers prevent that maturation, the cells keep pumping out interferons, which triggers the skin inflammation. Unlike classical psoriasis, which is driven by T cells, paradoxical psoriasis is an innate immune process that does not depend on T-cell autoimmunity.16Nature Communications. TNF blockade induces a dysregulated type I interferon response without autoimmunity in paradoxical psoriasis
The risk appears to vary depending on the underlying disease and the specific drug used. In patients with inflammatory bowel disease, onset of paradoxical psoriasis has been associated with female sex, the presence of other health conditions, and the use of adalimumab specifically. Genetic variation also plays a role, with certain gene variants increasing susceptibility.17PubMed Central. Paradoxical Psoriasis Induced by Anti-TNFα Treatment: Evaluation of Disease-Specific Clinical and Genetic Markers When paradoxical psoriasis occurs, the decision about whether to continue, switch, or stop the TNF blocker depends on how severe the skin eruption is and how well the drug is controlling the original disease.18PubMed Central. TNF Inhibitor-Induced Psoriasis: Proposed Algorithm for Treatment and Management
The Heart Failure Problem
Given that chronic inflammation contributes to cardiovascular disease, there was early hope that TNF blockers might help treat heart failure. Clinical trials testing this idea produced disappointing results and, in some cases, actually worsened outcomes. It turned out that at certain levels, TNF-α has cardioprotective effects: it helps heart muscle cells resist damage from oxidative stress and other insults. Blocking TNF-α in this context appeared to strip away that protection, making heart cells more vulnerable to injury.19PubMed Central. Acute heart failure as an adverse event of tumor necrosis factor inhibitor therapy in inflammatory bowel disease: A review of the literature
As a result, moderate to severe heart failure is considered a contraindication for TNF blocker therapy. Patients with mild heart failure may still use these drugs under close monitoring, but the cardiovascular risk is something doctors screen for before prescribing. This is a useful illustration of a broader principle: TNF-α is not purely destructive. It has legitimate functions in the body, and blocking it indiscriminately can have consequences in organs where it plays a protective role.
Pregnancy and TNF Blockers
For women of childbearing age with autoimmune diseases, the question of whether TNF blockers are safe during pregnancy comes up frequently. The answer depends on which drug is involved. Monoclonal antibodies like infliximab and adalimumab are built on an IgG1 antibody structure that is actively transported across the placenta, especially during the second and third trimesters. This means measurable levels of the drug can be found in the newborn’s blood at birth.20Elsevier / Reproductive Toxicology. How safe are the TNF alpha inhibitors with respect to pregnancy outcomes in autoimmune diseases?
Certolizumab pegol is the notable exception. Because it lacks the Fc fragment responsible for active placental transfer, very little of the drug crosses to the fetus. For this reason, certolizumab is often considered the preferred TNF blocker during late pregnancy when treatment cannot be interrupted. The practical implication is that pregnancy planning ideally includes a conversation about which TNF blocker to use, and in many cases, women on infliximab or adalimumab are switched to certolizumab or have their drug stopped early enough before delivery to let it clear from circulation.
Biosimilars and Cost
As the original patents on TNF blockers have expired, biosimilar versions have entered the market. Biosimilars are not generics in the traditional sense. Because biologic drugs are produced by living cells and are enormously complex molecules, a biosimilar has to demonstrate through rigorous testing that it matches the original in structure, function, and clinical performance.
A systematic review of phase 1 and phase 3 trials found that the pharmacokinetic properties of TNF blocker biosimilars fell within the prespecified equivalence range of their reference products, and clinical responses and side-effect profiles were similar.21PubMed. Bioequivalence of Biosimilar Tumor Necrosis Factor-α Inhibitors Compared With Their Reference Biologics: A Systematic Review A network meta-analysis of 18 randomized trials in rheumatoid arthritis, covering nearly 8,000 patients, confirmed comparable clinical outcomes between biosimilars and originators, with no meaningful difference in adverse events overall.22PubMed. Comparative efficacy and safety of tumor necrosis factor inhibitors and their biosimilars in patients with rheumatoid arthritis having an insufficient response to methotrexate
Real-world data from a large French national health database reinforced these findings, showing no increased risk of treatment discontinuation, infections, or hospitalization for patients on biosimilar versions of infliximab, etanercept, or adalimumab compared with those on the originator drugs.23PubMed Central. Persistence and safety of anti-TNF biosimilars versus originators in immune-mediated inflammatory diseases: an observational study on the French National Health Data System For patients, the most tangible benefit of biosimilars is cost. The original TNF blockers are among the most expensive drugs in routine use, and biosimilar competition has begun to bring prices down substantially, widening access for people who might otherwise have been unable to afford biologic therapy.
How TNF Blockers Compare to Newer Drug Classes
TNF blockers were the first targeted biologics for autoimmune disease, but they are no longer the only option. Newer drug classes target different parts of the immune cascade: IL-17 inhibitors, IL-23 inhibitors, and JAK inhibitors have all entered the field and are used for overlapping indications. A natural question is whether these newer drugs are safer or more effective.
The evidence so far suggests a complicated picture. In psoriatic arthritis and axial spondyloarthritis, a comparative study matching over 2,000 patients per group found that JAK inhibitors were not associated with a higher risk of cardiovascular disease or cancer compared to TNF blockers over three years of follow-up.24PubMed. Comparative safety of JAK inhibitors versus TNF or IL-17 inhibitors for cardiovascular disease and cancer in psoriatic arthritis and axial spondyloarthritis That said, in other populations, particularly older patients with cardiovascular risk factors, some regulatory agencies have flagged JAK inhibitors as carrying greater cardiovascular and malignancy risk, leading to guidance that TNF blockers should be tried first in many cases. The choice between drug classes often comes down to the specific disease, the patient’s other health conditions, prior treatment history, and practical considerations like whether the drug is injected at home or infused in a clinic.
TNF blockers remain the first-line biologic for many patients with rheumatoid arthritis, Crohn’s disease, and certain forms of psoriasis, partly because of decades of accumulated safety data and partly because they remain effective for a large share of patients. For those who do not respond or who lose response over time, switching to a different mechanism of action is a well-established strategy.
Selective TNF Blocking and Future Directions
One of the active frontiers in TNF research involves trying to block TNF-α more selectively. As noted earlier, all current TNF blockers bind to both the soluble form and the membrane-bound form of TNF-α. The membrane-bound form’s reverse signaling can cause immunosuppression, which is part of why current drugs increase infection risk.6Nature Communications. The structural basis for the selective antagonism of soluble TNF-alpha by shark variable new antigen receptors Researchers are working on next-generation molecules that would block only the soluble form, leaving the membrane-bound form and its protective granuloma-maintaining functions intact. One particularly inventive approach uses antibody-like proteins derived from shark immune systems, which naturally adopt a single-domain structure that can be engineered for high selectivity.
Similarly, there is interest in selectively targeting one TNF receptor over the other. TNFR1 signaling is more closely linked to inflammation and the differentiation of inflammatory T cells, while TNFR2 signaling supports the function of regulatory T cells that keep the immune system in check.25Cell Death & Disease. Differential roles of TNFα-TNFR1 and TNFα-TNFR2 in the differentiation and function of CD4+Foxp3+ induced Treg cells in vitro and in vivo periphery in autoimmune diseases A drug that blocked only TNFR1, in theory, could dampen the harmful inflammation while preserving the regulatory arm of the immune response. These approaches are still largely in preclinical development, but they represent a genuine attempt to solve the central limitation of current TNF blockers: the impossibility of turning off the bad without also turning off some of the good.